Trevi Therapeutics director Michael Heffernan sells $595,805 in stock
Michael Heffernan, a Trevi Therapeutics, Inc. (NASDAQ:TRVI) director, executed a significant transaction on September 15, 2026. He sold 39,473 shares of common stock, amounting to $595,805, through a Rule 10b5-1 trading plan that was approved on June 16, 2026. The stock was sold at a range of prices, from $15.09 to $15.88. In parallel, Heffernan exercised 39,473 stock options, valued at $126,103, with prices ranging from $3.04 to $3.33.
The company's shares had seen a 15.65% increase over the previous week, trading at $14.81 with a market capitalization of $2.13 billion. Despite the insider sale, Trevi Therapeutics remains a focus for investors, given its advancements in the chronic cough pipeline and its robust financial position.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
